Duda Melzer Talks about What it Takes to Run a Successful Family Business

Being grown in a family of entrepreneurs, Eduardo Sirotsky Melzer aka Duda Melzer has entrepreneurship in his blood. He has grown up seeing his grandfather set up the RBS Group that has become one of the biggest media company in the south of Brazil. Duda has worked hard to be able to be eligible for the post of CEO of the company that he was awarded in 2016. In a short amount of time, he has made some important decisions that will help the company to grow its product portfolio further.

Duda Melzer is also the founder and the chairman of the e.Bricks Digital that empowers business and companies in the digital world. The company has numerous clients from Brazil and the United States. Eduardo Sirotsky Melzer joined RBS Group in 2004 as the Director General for the National Market. Over the years and with his dedication, he rose to the rank of the Vice-president of the RBS Group in 2012. After his uncle, Nelson Pacheco, took retirement, he became the CEO of the company in 2016.

In an article on Dino, Duda Melzer was a studious student and completed his graduation from the top colleges in the country, the Pontifical Catholic University of Rio Grande do Sul or PUCRS. He then got admitted to Harvard University and earned his MBA degree. After his post-graduation, he did not return to Brazil immediately; he spends time working in a number of companies in the United States to gain experience. He has been lucky to have so many people in his life who have guided him to success. One of them is John Davis, his professor at the Harvard University who had a significant effect on him. Even after being a successful businessman, when asked about his actual accomplishment, he has just one thing to say – his family. He is married and has three loving children who adore him.

Follow their website eduardosirotskymelzer.com

See more: https://twitter.com/dudamelzer

Jason Hope: The Tech Mogul Of Scottsdale

The Tech Industry Of Scottsdale
Scottsdale, Arizona is changing and Jason Hope is a symbol of that change. The tech entrepreneur has made a name for himself as one of the most prominent names in Arizona’s equivalent of the Silicon Valley. Recently, Hope decided to add futurism to his long list of endeavors and now offers his opinions on the future of the tech industry. Jason Hope believes the Internet of Things, a term referring to the collection and exchange of data by appliances, will change the way we live our lives for good.

Where The Internet Of Things Factors In
IoT is a budding technology, but it isn’t hard to see where the future of this technology might take us. “Smart” devices around our homes are going to make us rethink the way we do just about everything. We already have televisions and mobile devices with embedded systems, but the real change will happen when we see this technology applied to things such as refrigerators and stovetops.

The Fight Against Aging
Beyond the Internet of Things, Hope is a strong believer in the fight against aging. Particularly, he has made himself a major contributor to the Strategies for Engineering Negligible Senescence Institute. The SENS Institute wants to change the way people view aging. Most people believe aging is simply a natural part of getting older, but the SENS Institute views it as a disease to eradicate. The search for ways to cure aging is an ongoing one, but the potential of this technology is far greater than any costs of research.

About Jason Hope
He sees technology as a way to solve the problems of the world and fundamental to progress. After graduating with a degree in finance from Arizona State University and a MBA W.P Carey School of Business, he decided to make a name for himself as a tech mogul.

Mikhail Blagosklonny: A Pre-Eminent Physician-Scientist

As one of the leading causes of death globally, cancer has attracted significant interests especially from scientists. The primary objective of these scientists is to find the cancer elusive treatment. One such scientist, who has made significant contributions towards tackling cancer, is Mikhail Blagosklonny: a specialist in cancer biology and treatment therapies. With his strong academic and research background, Mikhail Blagosklonny has made significant contributions in the fight against cancer, some of which have the potential of revolutionizing cancer treatment and aging.

Research Work

In addition, he has co-authored several book chapters and research reviews on cellular and molecular biology of cancer cells including their cycle, apoptosis and autophagy on tandfonline.com. His widely cited works also focus on molecular theory of aging. Towards this end, he proposed that target of rapamycin (TOR) signaling plays a significant role in prolonging cell life by inhibiting apoptosis, delaying autophagy and promoting cellular protein synthesis. These processes are vital in slowing down the aging process and hence delaying the onset of age-related diseases. Blagosklonny also proposed that since over-expression of TOR signaling inhibited autophagy leading to cancerous tumors, its regulation can help in cancer treatment. He believes understating these processes is vital in developing effective anti-cancer and anti-aging drugs.

Career and Education History

Mikhail Blagosklonny is also a scholar whose work extends beyond research.  His experience played a key role in his appointment as he had worked at Ordway Research Institute as research scientist. In 2002, his academic credentials on impactjournals.com as a specialist in internal and experimental medicine with both Doctor of Medicine and Philosophy (MD and PhD) degrees saw him being appointed as New York Medical College’s associate professor. His is an alumnus of the prestigious First Pavlov State Medical University of St. Petersburg where he received both of his degrees. Blagosklonny is the current editorial leader for three peer-reviewed scientific and medical journals published weekly, biweekly and monthly: Oncotarget, Cell Cycle and Aging, respectively.

Reference: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=3740